Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.
OlympiA- Phase 3, multicenter, randomized, placebocontrolled trial of adjuvant olaparib after (neo) adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow.
Impactful Shortlisted Abstracts/Publications in TNBC
Chairpersons :
Dr. B. K. Smruti, Dr. SVSS Prasad
Speaker :
Dr. Rushabh Kothari